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relevant apical endpoints. Transcriptional pathway BMDs 
could only be examined in males. These median BMDs 
ranged from 0.08 to 1.43 mg/kg bw/day and approximated 
those derived from traditional histopathology. MiR-34a (a 
P53 target) was the only microRNA significantly increased 
at the 2 mg/kg bw/day, providing evidence to support the 
importance of apoptosis and cell proliferation in furan hepa-
totoxicity. Overall, this study demonstrates the use of tran-
scriptional profiling to discern mode of action and mecha-
nisms involved in gender differences.
Keywords Low dose furan · Rat liver · Gender 
differences · Pathway benchmark dose · miRNA · Thryoid 
hormone
Introduction
Furan (CAS No. 110-00-9) is a colorless, volatile and lipo-
philic compound that is used as an intermediate in the syn-
thesis of many chemical and pharmaceutical agents, sol-
vents, lacquers and resins. Furan has also been detected in a 
broad variety of foods, particularly coffee, canned meats and 
baby food, with levels exceeding 100 parts per billion (Bakh-
iya and Appel 2010). Furan in food is thought to be gener-
ated from the decomposition of carbohydrate, fatty acid and 
ascorbic acid during heat treatment processes such as cook-
ing, canning and baking (Morehouse et al. 2008). In humans, 
furan has been detected in breast milk samples and in the 
breath of both smokers and passive smokers (NIH 2012).
Furan induces hepatocellular neoplasms and cholangio-
carcinomas (CC) in both rats (F344) and mice (B6C3F1) 
in standardized 2-year carcinogenesis studies (NTP 1993). 
CC accounts for about 10–15 % of human primary hepa-
tobiliary neoplasms worldwide (Chapman 1999), and 
Abstract Furan is a widely used industrial chemical and a 
contaminant in heated foods. Chronic furan exposure causes 
cholangiocarcinoma and hepatocellular tumors in rats at 
doses of 2 mg/kg bw/day or greater, with gender differ-
ences in frequency and severity. The hepatic transcriptional 
alterations induced by low doses of furan (doses below 
those previously tested for induction of liver tumors) and 
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the global hepatic mRNA and microRNA transcriptional 
profiles of male and female rats exposed to 0, 0.03, 0.12, 
0.5 or 2 mg/kg bw/day furan over 90 days. Marked gen-
der differences in gene expression responses to furan were 
observed, with many more altered genes in exposed males 
than females, confirming the increased sensitivity of males 
even at the low doses. Pathway analysis supported that key 
events in furan-induced liver tumors in males include gene 
expression changes related to oxidative stress, apoptosis and 
inflammatory response, while pathway changes in females 
were consistent with primarily adaptive responses. Pathway 
benchmark doses (BMDs) were estimated and compared to 
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CC-induced mortality has risen in the USA, Japan, Aus-
tralia and Europe from 1979 to 1998 (Khan et al. 2002). 
Given that human exposure to furan is ubiquitous and the 
margin of exposure of furan compared to other rodent 
carcinogens is small (Carthew et al. 2010), the potential 
impacts of furan for human health are of concern.
Gender differences in the incidence of hepatocellular 
neoplasms in rats exposed to furan occurred in the 2-year 
cancer study, with increased frequency in male rats (NTP 
1993). Benchmark dose (BMD) analysis of furan-induced 
hepatocellular carcinoma also indicated that male rats were 
more sensitive than females: estimated BMDs were 1.84 
and 5.49 mg/kg bw in male rats and female rats, respec-
tively (Carthew et al. 2010). Moreover, male rats exposed 
to 30 mg/kg bw furan for only 3 months from birth devel-
oped CC by 9 or 15 months of age (Maronpot et al. 1991).
Evidence in support of both genotoxic and non-genotoxic 
(hepatotoxicity and regenerative hepatocyte proliferation) 
modes of action (MoA) for furan toxicity have been reported 
(Hickling et al. 2010). Furan is negative for the induction of 
gene mutations in Salmonella typhimurium strains TA1535 
and TA1537, and equivocal in strains TA98 and TA100 (Lee 
et al. 1994; Ronto et al. 1992; NTP 1993). Furan also yields 
inconsistent genotoxicity results in eukaryotic cells: (a) it 
is negative for the induction of sex-linked recessive lethal 
mutations in germ cells of male Drosophila melanogaster 
in vivo, sister chromatid exchanges in B6C3F1 mouse bone 
marrow cells in vivo and unscheduled DNA synthesis in 
hepatocytes of mice and rats in vivo; and (b) it is positive 
for the induction of trifluorothymidine resistance in mouse 
L5178Y lymphoma cells, sister chromatid exchanges in 
Chinese hamster ovary cells and chromosomal aberrations 
in B6C3F1 mouse bone marrow cells in vivo (Wilson et al. 
1992; NTP 1993). Evaluation in rat livers in vivo suggests 
that genotoxicity from furan exposures may only occur 
at relative high doses via an indirect mechanism (Ding 
et al. 2012; McDaniel et al. 2012). Epigenetic alterations 
(DNA methylation and histone changes) are reported after 
180 days of exposure to furan (Conti et al. 2014). Furan 
induces hepatotoxicity and proliferation at 0.1 mg/kg bw 
(Mally et al. 2010; Moser et al. 2009; Wilson et al. 1992). 
The primary MoA of furan-induced CC at carcinogenic 
doses is thus proposed to be oxidative stress, cytotoxicity 
and increased hepatocyte proliferation (Ding et al. 2012; 
Hickling et al. 2010). Although existing evidence supports 
that cell cycle perturbation and apoptosis are also involved 
in the MoA of furan at low doses (Chen et al. 2010), con-
firming this finding and investigating whether other MoAs 
are relevant at lower doses and occur to a similar extent in 
both sexes is required to provide critical information for 
human health risk assessment of furan exposure.
The MoA of furan in the livers of female mice (note: 
female mice were analyzed because of high spontaneous 
rates of liver tumors in male mice) exposed to both carci-
nogenic and non-carcinogenic doses for 21 days has pre-
viously been explored using gene expression profiling 
(Jackson et al. 2014). Marked changes in gene expression 
pathways involved in cytotoxicity, oxidative stress, inflam-
matory response and proliferation were observed, which 
is consistent with previously published histological data 
in other studies (Gill et al. 2011; Moser et al. 2009). The 
results demonstrate a clear distinction between adaptive 
low-dose responses (cytoprotective effects invoked through 
balanced activation of proliferative signaling and regen-
eration, sustaining a healthy liver) and adverse responses 
at high doses (overt cytotoxicity/proliferation in parallel 
with increases in pathways associated with pre-cancer and 
cancer cells). The results were an effective demonstration 
of the use of toxicogenomic data in elucidating the MoA 
and BMDs for furan oral exposures. A study conducted 
in male and female rats exposed to much lower doses of 
furan observed mild hepatic histological lesions at doses 
≥0.12 mg/kg bw/day for 90 days (Gill et al. 2010). Clear 
gender differences were also observed in response to furan, 
with male rats exhibiting increased response over female 
rats for frequency of biliary hyperplasia and alterations of 
serum glucose, triglycerides, magnesium and thyroid hor-
mones (TH). The application of whole genome transcrip-
tional profiling (including non-coding RNAs) to explore 
the mechanism(s) and the influence of sex underlying 
furan-induced hepatotoxicity is an important next step in 
understanding the risk posed by human furan exposure.
The present study examines genomewide transcriptional 
responses in livers from our previous study of male and 
female F344 rats (Gill et al. 2010) exposed to furan by oral 
gavage over a 90-day period. Our analyses focused on the 
known lowest carcinogenic dose (2 mg/kg bw/day) and three 
lower doses. Livers from male and female rats from each 
dose were subjected to microarray analyses of mRNA and 
microRNA (miRNA) levels to assess global transcriptional 
changes. The transcriptional changes were directly related to 
various previously described phenotypic anchors to propose a 
mechanistically relevant transcriptional dose–response model. 
Gene expression changes were used to establish pathway 
BMDs to explore gender- and endpoint-specific responses for 
key events leading to furan-induced hepatotoxicity.
Materials and methods
Animals and exposures
Seven- to eight-week-old male or female F344 rats were 
exposed daily, 5 days per week, to furan in corn oil at doses 
of 0, 0.03, 0.12, 0.5 or 2 mg/kg/day by oral gavage for 
90 days. Animal handling and treatment procedures were 
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conducted according to the Guidelines of the Canadian 
Council of Animal Care and were approved by the Health 
Canada Animal Care Committee (Ottawa, ON, Canada). 
The full experimental details for this study, including his-
topathological and biochemical analyses, are reported else-
where (Gill et al. 2010). Liver samples were collected 24 h 
after the last exposure, flash-frozen and stored at −80 °C.
RNA extraction
Total RNA was extracted from frozen liver tissue of five 
male and five female rats from each dose group with mir-
Vana miRNA isolation kits (Ambion, Inc., Foster city, CA, 
USA) according to the manufacturer’s instructions. RNA 
integrity was determined using an Agilent 2100 Bioana-
lyzer (Agilent Technologies Inc., Mississauga, ON, Can-
ada), and only high-quality RNAs (RNA integrity num-
ber ≥8.0) were used for microarray analysis of gene and 
miRNA expression.
Microarray analysis of gene expression
A total of 50 RNA samples (five female and five male rats 
per dose group, five dose groups total) were labeled with 
cyanine 5-CTP using low-input quick amp labelling kits 
(Agilent Technologies Inc.) following the manufacturer’s 
instruction. Universal rat reference total RNA (Agilent 
Technologies Inc.) was labeled with cyanine 3-CTP. Cy5-
sample cRNA and Cy3-reference cRNA were hybridized to 
Agilent G4853A SurePrint G3 Rat GE 8 × 60 K micro-
arrays (Agilent Technologies Inc.) at 65 °C overnight with 
Agilent hybridization solution. Slides were washed and 
scanned on an Agilent G2505B microarray scanner at 5 μm 
resolution, and the data were acquired with Agilent Fea-
ture Extraction software version 10.7.3.1. One microarray 
from the male group failed standard quality checks and was 
eliminated from further analyses.
Raw signal intensity data were processed using R as 
described previously for data normalization, Fs calcula-
tion and p value adjustment with the false discovery rate 
(FDR, Paquette et al. 2011). The statistical model included 
gender and treatment as main factors as well as gender 
by treatment interactions. Genes were deemed to be ‘dif-
ferentially expressed’ if either treatment or gender effects 
had a FDR p ≤ 0.05. The least squares mean was used 
to estimate the fold change (FC) for each pairwise com-
parison of interest (control versus each of the four dose 
groups, Goodnight and Harvey 1997; Searle et al. 1980). 
To explore gender differences in gene expression, we iden-
tified significantly changed genes in each dose group com-
pared to control within each gender, followed by statistical 
analyses to determine the effect of gender. Cluster analysis 
was conducted with all significantly changed genes in all 
groups using GeneSpring GX 7.3 (Agilent Technologies 
Inc.). All data are available through the gene expression 
omnibus (GEO) website, accession number: GSE62808.
qRT‑PCR analysis of gene expression
Total RNA was reverse transcribed into cDNA using Super-
Script III (Invitrogen, Burlington, ON, Canada). Quantita-
tive PCR was performed in duplicate for each sample. A 
CFX96 real-time PCR detection system (Bio-Rad Labora-
tories, Mississauga, ON, Canada) was employed to detect 
SYBR green incorporation into amplified product. Gene 
expression levels were normalized to the housekeeping 
gene Hprt, which, based on microarray analysis, was unaf-
fected by furan exposure. PCR efficiency was examined 
using the standard curve for each gene. Primer specificity 
was verified with a melting curve. OpenStat (http://www.
statpages.org/miller/openstat/, a statistical program writ-
ten by William G. Miller) was used for ANOVA of mul-
tiple groups, while the Fisher’s least significant difference 
test was used to detect significant differences (p < 0.05) 
between control and a given dose group.
Pathways analysis
Enriched functional effects were identified by analyzing 
genes with FDR p ≤ 0.05 and absolute FC ≥ 1.5 relative to 
control in male and female rats exposed to furan at 2 mg/kg 
bw/day in Ingenuity Pathway Analysis (IPA, Ingenuity Sys-
tem, Inc., Redwood City, CA). We also applied IPA to the 
genes showing gender differences in expression at 2 mg/
kg bw/day. Identification of canonical pathways within the 
data was determined by the enrichment of genes associated 
with pathways among the group of altered genes. Signifi-
cance of the associated pathways was determined by IPA 
using a Fisher’s exact test (deemed significant if p ≤ 0.05). 
IPA predicted upstream modulators (including transcrip-
tion factors, cytokines and chemical exposures), and toxic-
ity functions were explored to identify potential regulators 
that might be consistent with the altered patterns of tran-
scription observed. Statistical significance for the potential 
upstream modulators and toxicity functions were expressed 
as a Z score, where significant activation or association was 
inferred from a Z score ≥2, and significant inhibition or 
inverse associations from Z score ≤−2.
Functional annotation clustering to look at broad trends 
in expression patterns in males versus females was con-
ducted using DAVID bioinformatics response 6.7 (Huang 
da et al. 2009a, b). The analysis was applied to genes that 
were significantly different in control males versus control 
females (FDR p ≤ 0.05 and absolute FC ≥ 1.5).
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Similarity to disease states or toxicity of other 
substances
Genes observed to be significantly altered (FDR 
p ≤ 0.05 and absolute FC ≥ 1.5) in either male or 
female rats from the 2 mg/kg bw/day dose group were 
uploaded into NextBio (http://nextbio.com) to iden-
tify disease states and/or chemicals with similar gene 
expression profiles using curated datasets. FC values (vs. 
control) were converted to ranks across the entire dataset 
and compared pairwise to curated datasets to generate a 
percent similarity metric.
Determination of BMD for apical endpoints
The BMD (the estimated dose that caused a 10 % or 1 SD 
(standard deviation) change in observed responses) and the 
95 % lower confidence limit (BMDL) for the apical end-
points of furan exposure observed in the rats used in the 
current study (Gill et al. 2010) were calculated using EPA 
BMDS 2.5 (Davis et al. 2011). Briefly, continuous dose–
response models (Hill, polynomial, linear, power and 
exponential) and dichotomous models (gamma, logistic, 
loglogistic, logprobit, multistage, multistage-cancer, probit, 
weibull and quantal-linear) were applied for each endpoint, 
and BMDs were decided based on goodness-of-fit p value 
≥0.1, absolute scaled residual ≤2 and visual curve inspec-
tion. When more than one model was suitable, the one 
with the lowest Akaike’s information criterion (AIC) was 
selected.
Transcriptional BMD analysis
BMDExpress version 1.4.1(Yang et al. 2007) was used to 
calculate transcriptional BMDs and BMDLs. Briefly, genes 
observed to be significantly altered (ANOVA p ≤ 0.05 
filtered) by any dose of furan exposure in either males or 
females were input into BMDExpress and evaluated by 
five models: Hill, power, linear 1°, polynomial 2° and 3°. 
For each probe, the best-fitting model was selected based 
on: (1) a nested Chi-square cutoff value of 0.05 to select 
between linear and polynomial models; (2) the lowest AIC 
to select between Hill and power models; and (3) a good-
ness-of-fit p value ≥0.1. Other parameters used included 
power restriction of ≥1, maximum iteration of 250, con-
fidence level of 0.95 and a benchmark response (BMR) 
of 1.349 (the number of standard deviation defining the 
BMD, Yang et al. 2007). A Hill model was flagged if the 
“k” parameter was >1/3 of the lowest dose. The next best 
model with goodness-of-fit p value ≥0.1 was selected in 
place of a Hill model. If no other model had a goodness-of-
fit p value ≥0.1, the Hill model was used and modified to 
0.5 of the lowest BMD value. The resulting BMD datasets 
were mapped to IPA pathways (downloaded on April 24, 
2014) to obtain functional classifications. Not all genes 
could be modeled, only BMDs that were less than the high-
est exposure dose and that had a goodness-of-fit p value 
≥0.1 were included in subsequent analyses.
miRNA microarray analysis
To explore the effects of furan on miRNA transcription, 
total RNAs from 16 liver samples (four males and four 
females from control and 2 mg/kg bw/day dose groups) 
were processed using the miRNA Complete Labelling and 
Hybridization kit (Agilent Technologies Inc.). Labeled 
RNA was hybridized on 8 × 15 K Agilent rat miRNA 
microarray slides. Arrays were scanned using an Agilent 
G2505B scanner (5 μm resolution). Feature extraction 
(version 10.7.3.1, Agilent Tech. Inc.) was used to acquire 
the fluorescence intensity of each probe.
The quality of the microarray data was evaluated using 
Agilent Feature extraction quality control metrics. Data 
were normalized in R using cyclic-lowess (Bolstad et al. 
2003). Ratio–intensity plots, boxplots and cluster analyses 
were used to identify potential outliers. All samples passed 
the quality control tests and were used for subsequent anal-
yses. Statistically significantly altered miRNAs were iden-
tified as described previously for gene expression. All data 
are available through the gene expression omnibus (GEO) 
website, accession number: GSE62807.
qRT‑PCR analysis of differentially regulated miRNAs
The miScript PCR system (Qiagen, Mississauga, ON, 
Canada) was used to examine the expression of miRNAs. 
Briefly, 1 μg of total RNA was used for polyadenylation of 
mature miRNAs and reverse transcription into cDNA using 
oligodT primers with a universal tag. RT-PCR was per-
formed in duplicate for each sample using a primer com-
plementary to the universal tag and a miScript primer assay 
specific to each miRNA. RNU6B was used to normalize 
the expression of the target miRNAs. FC was calculated 
using the 2−Ct method (Livak and Schmittgen 2001), 
and a student’s t test was used for statistical significance.
Results
General effects of furan on gene expression in rat livers
The number of hepatic transcripts significantly (abso-
lute FC > 1.5; FDR p ≤ 0.05) altered by furan exposure 
in rats increased with dose in both genders (Fig. 1a). FCs 
ranged from +10.52 to −5.93 for furan-treated relative to 
control rats. In female rats, genes that were affected in the 
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lower-dose groups were generally affected in one or more 
of the higher-dose groups (Fig. 1b). In male rats, there 
were more responsive genes overall, and an increase in the 
number of genes that were uniquely affected within a dose 
group (Fig. 1c). The full lists of significantly altered genes 
(absolute FC ≥ 1.5 and FDR p ≤ 0.05) in females and 
males are shown in supplementary Table_S1 and Table_S2, 
respectively. The vast majority of gene expression changes 
were observed in the highest dose group, and of these, the 
majority were unique to the highest dose. Indeed, ~93 % of 
genes in both females (171/184) and males (569/617) were 
unique to the highest dose, indicating a clear transition in 
the nature of the transcriptional response to the 2 mg/kg/
day dose of furan treatment.
Five genes were selected to validate microarray results 
using qRT-PCR (Table 1). These genes either had high FCs 
in male and/or female rats (Abcb1b, Cyp3a62 and Akr7a3) 
or in the case of Pparα and Fabp7 were related to the 
most affected pathway (LPS/IL-1-mediated inhibition of 
RXR function, Table 2). The qRT-PCR results were highly 
consistent with those from DNA microarrays for all five 
genes. The only exception was a detected increase in the 
expression of Pparα in the highest dose group of females 
by qRT-PCR that was missed by DNA microarray analysis 
(Table 1).
Pathways affected by furan exposure in male 
and female rats
Pathway analysis was conducted on genes with FDR 
p ≤ 0.05 and absolute FC ≥ 1.5 in males or females 
separately. With a pathway enrichment cutoff value of 2 
[−log (p value)], only four (or fewer) canonical pathways 
were affected in the low-dose groups (data not shown). 
In females and males, 17 and 45 pathways, respectively, 
were affected by 2 mg/kg bw/day furan (Table 2); 65 % of 
the affected pathways in females were also significantly 
perturbed in males, including the LPS/IL-1-mediated 
inhibition of RXR and NRF2-mediated oxidative stress 
response pathways. Significant enrichment of biological 
functions, toxicological pathways or upstream activators 
with Z score ≥2 or ≤−2 and p < 0.05 only occurred in the 





























































Fig. 1  Number of significantly (FDR p ≤ 0.05) changed gene with 
absolute FC ≥ 1.5. a Dose-dependent increases in the number of 
genes that were differentially expressed in both genders relative to 
vehicle controls for increasing doses of furan were observed. b Venn 
diagrams showing the overlap of furan-responsive genes in each dose 
group in female rats. c Venn diagrams showing the overlap of furan-
responsive genes in each dose group in male rats
Table 1  Fold changes for select 
genes analyzed by microarray 
or real time RT-PCR
Bold font indicates p < 0.05 compared to control
Furan (mg/kg bw/day) Akr7a3 Abcb1b Cyp3a62 Pparα Fabp7
Female Male Female Male Female Male Female Male Female Male
Microarray
 0.03 1.08 1.31 1.26 −1.04 1.12 1.41 1.3 1.42 −1.14 1.06
 0.12 1.05 1.12 1.42 1 1.25 1.12 1.43 1.76 −1.11 1.06
 0.5 1.36 2.14 2.32 2.02 1.3 1.61 1.42 1.7 −1.52 −1.15
 2 2.88 7.05 5.76 5.74 3.01 3.15 1.32 1.84 −2.07 −2.27
RT-PCR
 0.03 1.61 2.18 2.26 1.41 1.05 1.03 1.51 1.54 1.14 1.25
 0.12 1.96 0.76 2.09 0.67 1.12 1.60 1.52 1.14 1.22 −2.97
 0.5 0.81 3.34 2.66 10.23 1.85 1.70 0.95 2.64 −3.05 −1.54
 2 3.82 16.65 40.82 35.11 3.07 3.49 2.48 3.27 −2.76 −3.22
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Table 2  Canonical pathways affected by furan at 2 mg/kg bw/day in males and females
Female Male
Ingenuity canonical pathways −log (p value) Ratio Ingenuity canonical pathways −log (p value) Ratio
Glutathione-mediated detoxification 2.99 0.07 LPS/IL‑1‑mediated inhibition of RXR  
function
11 0.114
LPS/IL‑1‑mediated inhibition of RXR  
function
2.97 0.03 Acute phase response signaling 8.25 0.116
NRF2‑mediated oxidative stress response 2.73 0.03 Nicotine degradation II 6.23 0.129
Hepatic fibrosis/hepatic stellate cell activation 2.49 0.03 LXR/RXR activation 6.05 0.108
Aryl hydrocarbon receptor signaling 2.48 0.03 Coagulation system 5.49 0.211
Histamine degradation 2.42 0.07 Bupropion degradation 5.39 0.212
Fatty acid α oxidation 2.24 0.09 Acetone degradation I (to methylglyoxal) 5.27 0.194
Oxidative ethanol degradation III 2.24 0.05 Nicotine degradation III 5.05 0.123
Putrescine degradation III 2.19 0.07 PXR/RXR activation 4.95 0.109
2-Amino-3-carboxymuconate semialdehyde 
degradation to glutaryl-CoA
2.15 0.09 Melatonin degradation I 4.84 0.136
Methylglyoxal degradation VI 2.15 0.08 Xenobiotic metabolism signaling 4.82 0.073
Tryptophan degradation X (Mammalian, via 
Tryptamine)
2.14 0.07 FXR/RXR activation 4.72 0.1
Ethanol degradation IV 2.14 0.07 Complement system 4.64 0.2
Acute phase response signaling 2.13 0.03 Superpathway of melatonin Degradation 4.52 0.111
cardiomyocyte differentiation via BMP  
receptors
2.10 0.09 Methylglyoxal degradation III 4.48 0.227
Granulocyte adhesion and diapedesis 2.08 0.03 Estrogen biosynthesis 4.22 0.143
RAR activation 2.05 0.03 Tryptophan degradation X (mammalian, via 
tryptamine)
4.05 0.172
Ethanol degradation II 3.66 0.14
Bile acid biosynthesis, neutral pathway 3.52 0.069
Noradrenaline and adrenaline degradation 3.44 0.113
Dopamine degradation 3.42 0.132
Extrinsic prothrombin activation pathway 3.14 0.182
Oxidative ethanol degradation III 3.14 0.1
Intrinsic prothrombin activation pathway 3.09 0.135
Ethanol degradation IV 2.93 0.138
Serotonin degradation 2.92 0.09
Aryl hydrocarbon receptor signaling 2.84 0.064
Retinol biosynthesis 2.64 0.111
Granulocyte adhesion and diapedesis 2.57 0.066
NRF2‑mediated oxidative stress response 2.45 0.062
Inhibition of matrix metalloproteases 2.43 0.125
Thyroid cancer signaling 2.38 0.114
Serine biosynthesis 2.38 0.154
d-Glucuronate degradation I 2.38 0.143
EIF2 signaling 2.37 0.06
Histamine degradation 2.34 0.103
Atherosclerosis signaling 2.24 0.065
Fatty Acid α oxidation 2.08 0.13
Putrescine degradation III 2 0.1
Proline biosynthesis II (from arginine) 2 0.1
Superpathway of serine and glycine  
biosynthesis I
2 0.111
Arginine degradation VI (arginase 2 pathway) 2 0.125
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in males at this dose resulted in more enriched molecular 
pathways/functions in males than females (Table 3). Male 
rat livers exposed to 2 mg/kg bw/day showed significant 
enrichment in 74 biological functions primarily related to 
inflammation and metabolism (supplementary Table_S3). 
In contrast, there was no significantly enriched biologi-
cal function in females. Six toxicological pathways were 
enriched in males in the 2 mg/kg bw/day dose group; 
most of these were related to liver function (supplemen-
tary Table_S4).
Analysis of potential upstream regulators revealed 27 
upstream modulators that were activated and 25 that were 
inhibited in males (supplementary Table_S5). These could 
be classified into various groups: chemicals and drugs, 
reagents, transcriptional regulators and endogenous hor-
mones. Most of these were related to regulation of apopto-
sis, proliferation and cancer processes. Expression profiles 
were indicative of activation of five and inhibition of six 
upstream modulators in females (supplementary Table_
S5). Only a few of upstream modulators were in com-
mon between the genders (RBPJ, CREB1 and 1,2-dithiol-
3-thione; these are all involved in cell proliferation and 
apoptosis). Overall, pathway analysis indicated inflamma-
tory and oxidative stress response, metabolism and cell 
proliferation pathways play important roles in the toxicity 
induced by furan in both genders. The pathway analysis 
further showed these processes and regulatory pathways 
were more perturbed in livers of male rats than female rats 
following furan exposure.
Prediction of potential disease outcomes and chemicals 
with similar toxicity and pathways
Significantly changed genes with absolute FC ≥ 1.5 in 
male and female rats treated with 2 mg/kg bw/day furan 
were analyzed using NextBio (http://nextbio.com) to iden-
tify similarities in the expression profiles with curated stud-
ies. Phenotypes with scores >70 and at least three studies 
available for the disease model (only liver tissue in rodents 
was included) were considered. Disease models with simi-
lar gene expression profiles to furan-treated rats are shown 
in Table 4. Although all of the disease models identified 
as correlated with gene expression profiles in females 
were also correlated with males, these models were nega-
tively correlated in females and positively correlated in 
males. This may indicate adaptive responses occurring in 
females versus adverse effects in males at this dose. The 
gene expression profile of the high-dose male rats was 
highly positively correlated with liver cancer, exhibiting the 
highest overall score as calculated from 55 similar studies. 
These studies included transgenic myc-driven liver tumors 
(GSE28198, 2011) and intrahepatic cholangiocarcinomas 
formed by inoculation of malignant rat cholangiocytes 
into liver (Dumur et al. 2010). Liver regeneration, injury of 
liver, inflammatory disease and cirrhosis were also highly 
positively correlated with furan treatment in male rats. 
Overall, these results are consistent with the hypothesis that 
furan induces liver injury, inflammation, regeneration and 
cancer in male rats.
−log (p value) cutoff at 2, bold font indicates common pathways between males and females, ratio indicates the number of significant genes to 
the total number of genes in the pathway
Table 2  continued
Female Male
Ingenuity canonical pathways −log (p value) Ratio Ingenuity canonical pathways −log (p value) Ratio
Superoxide radicals degradation 2 0.25
Tyrosine degradation I 2 0.133
Bladder cancer signaling 2 0.072
Table 3  Enriched pathways, functions and activators in the differentially expressed gene lists from male and female rats exposed to 2 mg/kg 
bw/day furan
Cut off vale: activation Z score ≥2 or ≤−2
* Number of elements common with male
Categories Male Female
Increase Decrease Increase Decrease
Biological functions 18 (liver injury and inflammation, cell death) 56 (lipid metabolism, hormone oxidation) 0 0
Toxicological functions 4 (liver injury and inflammation, cell death) 2 (liver hemorrhaging) 0 0
Upstream activators 27 25 5 (2*) 6 (1*)
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NextBio was also used to explore the similarity of gene 
expression profiles in rat livers treated with furan in the 
current study with other chemicals in the curated database. 
Using a cutoff score ≥80 and a requirement of at least three 
studies per chemical, we identified the chemicals inducing 
similar toxicity profiles to furan in male and female rats 
(supplementary Table_S6). The top five chemicals with 
the most similar profiles to furan-exposed male rats in our 
study are thioacetamide (TAA), nafenopin, methapyrilene 
(MP), mestranol and chloroform; these chemicals are all 
non-genotoxic carcinogens. The non-genotoxic carcino-
gens carbon tetrachloride (CCl4) and bromobenzene (BBZ) 
also induce similar gene expression profiles to furan treat-
ment in male rats.
Transcriptional BMD and apical endpoint BMD 
analysis
BMDExpress was used to establish transcriptional BMDs 
for furan. The responses were grouped using IPA path-
ways. BMD filtering included (1) pathways had to contain 
at least 10 genes; (2) at least five genes in the pathways 
had to exhibit a BMD ≤ 2 mg/kg bw/day and goodness-
of-fit p value ≥0.1, as well as the percentage of genes 
modeled in the pathways had to account for at least 3 % 
of the pathway’s genes (however, we included small path-
ways if the number of genes that were significant and could 
be modeled accounted for at least 20 % of the pathway); 
and (3) pathways were excluded if the Hill model was the 
only model used for all of the genes within a pathway. 
There were 56 pathways that met all of the above criteria 
in males (supplementary Table_S7). The most sensitive 
pathway (i.e., lowest BMD) was MAPK signaling with a 
median BMD 0.08 mg/kg bw/day. No pathway passed the 
stringent filtering criteria in females. However, BMDs for 
16 pathways were produced in females (supplementary 
Table_S7) when we loosened the stringency for the second 
criteria, instead requiring at least two genes or 1 % of the 
pathway affected. Half of these pathways were modeled in 
males too. The use of different filtering criteria to derive 
the pathway BMDs in males and females means the BMDs 
are not directly comparable, but provides a general view of 
the BMDs for females.
BMDs for apical endpoints (from our previous data, 
Gill et al. 2010) were calculated using EPA BMDS2.5. 
These were aligned to pathways that were representa-
tive of the apical endpoints. Apical and transcriptional 
BMDs were very close for liver cell damage and apopto-
sis, hepatocyte inflammation and biliary tract effects in 
male rats (Table 5). In females, apical endpoint BMDs 
for cholangiofibrosis and biliary tract hyperplasia were 
>2 mg/kg bw/day (supplementary Table_S8), while apical 
endpoint BMDs for Kupffer cell pigmentation and hepato-
cyte apoptosis were 0.11–0.20 mg/kg bw/day. As shown 
Table 4  Diseases with similar gene expression profiles to rats treated with 2 mg/kg bw/day furan
Bold and italics font indicates common disease models between males and females
R refers to correlation. n indicates negative correlation, p indicates positive correlation
Only rodent liver tissues were included in this analysis
# Studies indicates the number of studies included in calculating phenotypes score
Female Male
Phenotype score Phenotype # Studies R Phenotype score Phenotype # Studies R
72.50 High fat diet 20 n 99.03 Liver cancer 55 p
70.04 Diabetes mellitus 32 n 89.80 High fat diet 30 p
69.98 Disorder of endocrine pancreas 33 n 85.17 Disease due to trypanosomatidae 6 p
69.42 Injury of liver 5 n 84.96 Injury of liver 3 p
82.24 Inflammatory disease of liver 14 p
79.16 Disease due to rotavirus 3 p
78.19 Infection due to enterobacteriaceae 18 p
77.43 Cirrhosis of liver 11 p
77.19 Liver regeneration 4 p
75.81 Hepatic fibrosis 11 p
74.62 Deficiency state 22 p
73.90 Disease due to adenovirus 3 p
73.29 Diabetes mellitus 48 p
73.28 Disorder of endocrine pancreas 50 p
71.09 Bacterial infectious disease 8 p
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in supplementary Table_S7, we did not find any transcrip-
tional BMD that were directly related to cell cycle regula-
tion and apoptosis in females. Transcriptional and apical 
endpoint BMDs were not similar in females as there was 
an insufficient response to furan exposure at the doses 
used in current study.
miRNA expression in rat livers treated with furan at a 
dose of 2 mg/kg bw/day
Since miRNAs play important roles in the regulation of 
hepatocellular carcinomas (D’Anzeo et al. 2014) and 
other biological functions, we examined the effects of 
furan on miRNA expression at the highest dose in both 
sexes. Only miR-34a achieved a FDR p ≤ 0.05 and abso-
lute FC ≥ 1.5 in either male or female rats based on 
microarray analyses that showed miR-34a increased by 
2.4-fold in both genders. miRNA results were examined 
in more detail by qRT-PCR for miR-34a and three other 
miRNAs (miR-122 and miR-200a/b) that were perturbed 
by 30 mg/kg bw/day furan treatment over 3 months in 
male Sprague-Dawley (SD) rats in another study (Chen 
et al. 2012). qRT-PCR results confirmed the increased 
expression of miR-34a in both genders and also showed 
an increase in the expression of miR-200b in male rats 
only (Fig. 2).
The effect of furan on TH homeostasis
Our previous work showed that furan exposure induced 
a significant increase in serum T4 levels in male rats at 
doses ≥0.12 mg/kg bw/day, but caused no significant 
change in female rats (Gill et al. 2010). To further inves-
tigate the implications of furan exposure on TH func-
tion, we examined the effects of furan on the expression 
of four genes that are directly regulated by TH in rat liver 
(Dio1, Thrsp, Mlxipl and Me1). Thrsp expression in males 
and Me1 expression in females were down-regulated, in 
contrast to the observed increase in serum T4 concentra-
tions in rats treated with 2 mg/kg bw/day furan. qRT-PCR 
Table 5  Comparison of apical and transcriptional BMDs in furan-treated males
“# of genes modeled” indicates the number of genes that were significant by ANOVA and could be modeled (i.e., filtered to include genes with 
BMDs less than the highest dose of 2 mg/kg bw and p value of fit ≥0.1)
“Total # of genes in pathway” indicates all of the genes that are involved in the entire pathway
Pathways Transcriptional BMD(L)s Apical BMD(L)s
# of genes modeled 
(total # of genes in 
pathway)
BMD median  
(mg/kg bw)
BMDL median  
(mg/kg bw)
Apical endpoints BMD (mg/kg bw) BMDL (mg/kg bw)
Cell damage and 
apoptosis
p38 MAPK  
signaling











8 (169) 0.62 0.47
Inflammation
LPS/IL-1-mediated 
inhibition of  
RXR function




11 (157) 1.22 0.83
Biliary tract  
damage











2 (10) 1.43 0.94
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validation of these targets was consistent with the micro-
array results and also showed significant decreases in the 
expression of Dio1 and Mlxipl in males in one or more 
dose groups (Fig. 3). The results indicate that exposure 
to furan resulted in the down-regulation of TH-responsive 
genes in both females (Me1, Mlxipl) and males (Dio1, 
Thrsp, Mlxipl) despite the observed increase in serum T4 
levels only in males.
Gender differences in response to furan treatment
Analysis of basal gene expression differences between con-
trol males and females revealed a total of 958 genes that 
were significantly different between genders (FC ≥ 1.5; 
FDR p ≤ 0.05; Supplementary Table_S9). There were 594 
genes with higher transcript levels in females and 364 lower 
relative to males. The top three genes that were higher in 
Fig. 2  Analysis of miRNA 
changes using qRT-PCR. 
RNU6B was used to normal-
ize the expression of the target 
miRNAs. Three samples from 
each group were used. Copy 
number was represented with 
average ± SD. Experiments 
were repeated three times and a 
single representative is shown 

























Fig. 3  Expression of TH-regu-
lated genes. RNA samples from 
five female and five male rats in 
each dose group were examined 
with qRT-PCR. Each sample 
was analyzed in duplicate and 
experiments repeated three 
times. Representative results are 
shown. *p ≤ 0.05
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females were aldo–keto reductase family 1, member B7 
(Akr1b7: 588-fold higher in females), cytochrome P450, 
family 2, subfamily c, polypeptide 12 (Cyp2c12: 123-fold) 
and sulfotransferase family 2A, dehydroepiandrosterone 
(DHEA)-preferring, member 2 (Sult2a2: 115-fold). There 
were 14 transcripts with over a hundred-fold greater levels 
in males than females including the following: cytochrome 
P450, family 3, subfamily a, polypeptide 2 (Cyp3a2: 768-
fold); cytochrome P450, family 4, subfamily a, polypeptide 
2 (Cyp4a2: 619-fold); alpha-2u globulin PGCL2, PGCL3, 
PGCL5 and alpha-2u globulin (283-fold, 429-fold, 265-
fold and 386-fold, respectively); and several of the major 
urinary proteins (Mup4 and Mup5; 265-fold and 154-fold, 
respectively).
Functional annotation clustering of these genes was 
applied to examine the broad overall trends in the path-
ways, functions and processes that differed between the 
sexes (control samples) that might lead to gender-specific 
responses to furan. The top two functional annotation clus-
ters of genes that were expressed at higher levels in females 
than in males were involved in lipid and fatty acid metabo-
lism (data not shown). The third cluster was associated with 
genes involved in xenobiotic metabolism, including signifi-
cant overrepresentation of alcohol dehydrogenases (e.g., 
increased expression of Adh1, Adh4, Adh5, Adh6, Adh7) 
and genes involved in phase 2 xenobiotic metabolism (e.g., 
Gsta5 was 15-fold higher in females than males). In con-
trast, the top functional clusters that were higher in males 
than females were also associated with xenobiotic metabo-
lism, but this enrichment accounted for a very large number 
of phase 1 metabolic genes. In total, of the 19 cytochrome 
p450s exhibiting different transcript levels between gen-
ders, 15 of these were greater in male rat livers. Increased 
female transcription was only found for Cyp2c12 (123-fold 
greater in females), Cyp26a1 (9-fold greater), Cypd3a9 
(eightfold) and Cyp2r1 (twofold). There were also some 
phase 2 genes that were greater in males. In particular, 
Gstm1, Gstm2, Gstm3 and Gstm4 were all greater in males 
than females.
We then explored gender differences in response to 
the furan treatment. Males exhibited 4–8 times more dif-
ferentially expressed genes than females in the various 
treatment groups (Fig. 1a). Only a few genes were simi-
larly perturbed in males and females in the lower-dose 
groups, while one-third of the genes that were differentially 
expressed in females were in common with males at 2 mg/
kg bw/day (Fig. 4). Cluster analysis of all samples using all 
significantly changed genes indicated that the samples were 
distinctly split into two groups determined by sex (supple-
mentary figure_S1).
To further examine gender differences in gene expres-
sion, we analyzed the effect of gender using MANOVA 
in R for the high-dose groups (2 mg/kg bw/day). We first 
determined differences between the exposed and con-
trol groups within gender separately, and then used the 
combined list to statistically analyze differences between 
the genders. Setting a cutoff value of FDR p ≤ 0.05 and 
absolute FC ≥ 1.5 between genders, 132 genes that were 
disregulated by furan treatment exhibited significantly 
different responses between the genders (supplementary 
Table_S10). Of these, 86 % of the genes were significantly 
changed by furan in males only, 10 % were unique to 
females and the remaining 4 % were altered (but to a dif-
ferent extent) in both genders. The most affected gene that 
was modulated by a treatment–gender interaction was met-
allothionein 2A (Mt2a), which showed a 9.4-fold increase 
in response to furan in males relative to controls, but no 
significant response to furan treatment in females. Inter-
estingly, substantial gender differences in baseline expres-
sion levels of most of the genes in the top of the list were 
observed. These genes had higher basal expression levels in 
females, and furan treatment up-regulated their expression 
in males, such as Cyp2c12 and Akr1b7. On the other hand, 
the genes listed in the bottom of supplementary Table_S10 
had higher basal expression in males, and furan exposure 
down-regulated their expression in males. These results 
provide potential mechanistic clues for the sensitivities that 
can be attributed to both differences in basal and induced 
expression changes.
To further elucidate the mechanisms underlying gender 
differences following furan treatment, pathway analysis 
on the 132 genes (supplementary Table_S10) that were 
different between the genders in the 2 mg/kg bw/day dose 
groups was conducted. The pathways that responded dif-
ferently between the genders are shown in Table 6. Dif-
ferences in the sexes occurred in pathways involved in 
oxidative stress response and metabolism. Consistent with 
previous work demonstrating that serum TH levels were 
altered in male rats alone (Gill et al. 2010), pathway anal-
ysis revealed that furan-induced abnormal TH metabo-
lism was impacted by gender. The results were consistent 
with the pathway analysis that was conducted separately 
in males and females (Table 2), which indicated that 
although 65 % of the pathways perturbed in females were 
0.03 mg/kg 0.12 mg/kg 0.50 mg/kg 2.00 mg/kg
2 0 3 3 2 41 12 1 43 122 63 553
Females Males
Fig. 4  Venn diagram showing the overlap of significantly changed 
genes (FDR p ≤ 0.05 and absolute FC ≥ 1.5) in each dose group 
between genders
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also altered in males, the extent was different between 
genders.
Discussion
We investigated transcriptional changes occurring in the 
livers of rats of both sexes treated with furan at the known 
lowest tested cancer-causing dose and several lower doses 
for 90 days using DNA microarrays. The transcriptional 
profiles, pathway perturbations and BMDs provide insight 
into the MoA and gender differences in response to furan. 
The data support a similar MoA in rats to that proposed in 
our previous study in mice for furan-induced hepatocar-
cinogenesis. BMDs for both apical and transcriptional end-
points associated with this MoA are highly consistent in 
males. The data reveal that very few miRNAs are perturbed 
in the liver following subchronic furan exposure in rats. In 
addition, the effects of furan on TH status are paradoxical.
Proposed MoA for furan‑induced carcinogenicity
Previous global gene expression profiling in our laboratory 
on female mice exposed to furan for 21 days supported a 
MoA for hepatocarcinogenesis that involves pathways 
related to generation of reactive oxygen species causing 
cytotoxicity, inflammation and regenerative proliferation 
(Jackson et al. 2014). In the current study on rats, path-
way analysis clearly demonstrated induction of an oxida-
tive stress response (NRF2 mediated) and inflammation 
(LPS/IL-1 mediated) in both genders, although the extent 
was greater in male rats. The median transcriptional BMD 
for NRF2-mediated oxidative stress response in males was 
nearly one half that in females (0.62 vs. 1.12 mg/kg bw/
day), supporting that males are more sensitive to furan-
induced oxidative stress. These results suggest a similar 
MoA for furan-induced hepatotoxicity in rats and mice.
NextBio analysis revealed that TAA, nafenopin, MP, 
mestranol, chloroform, CCl4 and BBZ, all non-genotoxic 
hepatocarcinogens, exhibited similar gene expression pro-
files to furan in male rats (supplementary Table_S6). These 
non-genotoxic hepatocarcinogens act through glutathione 
depletion and induction of oxidative stress (Uehara et al. 
2010), inflammatory response, apoptosis and cell prolifera-
tion (Dragan et al. 1996; Fujii et al. 2010; Gill et al. 1998; 
Golden et al. 1997; Larson et al. 1996). This evidence sup-
ports that furan operates through a non-genotoxicity, or 
indirectly genotoxic, mechanism mediated through oxida-
tive stress to induce hepatocarcinogenesis. Interestingly, 
Cyp2e1 plays key roles in the metabolism of both TAA and 
CCl4 to reactive metabolites (Ramaiah et al. 2001), con-
sistent with the metabolic activation of furan by Cyp2e1 
(Bakhiya and Appel 2010). Metabolism of Cyp2e1-specific 
substrates leads to oxidative stress, inflammation and cyto-
toxicity. Prolonged activation of these processes would 
cause chronic cytotoxicity potentially leading to hepato-
carcinogenesis (Kim et al. 1990; Kim and Novak 1993; Ma 
et al. 2014; Porter et al. 1989; Song et al. 1986).
The above evidence suggests that a cytotoxicity mech-
anism mediated through oxidative stress predominates 
in furan-induced hepatotoxic effects. However, our gene 
expression data also support a role for genotoxicity in 
furan-induced hepatotoxicity in males. Specifically (1) P53 
was identified as an activated upstream regulator of furan 
effects (supplementary Table_ S5) in male rats treated with 
2 mg/kg bw/day; (2) Ccng1, Fas and Cdkn1a, which all 
play roles in DNA damage response and other pathways, 
were significantly up-regulated in male rats at the highest 
dose; (3) P53 upstream pathways, such as P38 Mapk and 
Erk Mapk pathways, were among the most sensitive path-
ways identified using a BMD approach; and (4) miR-34a 
(P53 target miRNA) is significantly up-regulated. Inter-
estingly, the DNA-damage-inducible gene Gadd45g was 
significantly down-regulated in males at the three highest 
doses. Gadd45g is a tumor suppressor gene that is dis-
rupted in multiple tumor types (Sun et al. 2003; Ying et al. 
2005); its down-regulation may have implications in the 
increased susceptibility of males to cancer.
Table 6  Pathways demonstrating gender-specific effects in rats treated with 2 mg/kg bw/day furan
−log (p value) cutoff at 1.7, ratio indicates the percentage of genes changed significantly in their response to furan between genders to total 
genes involved in the pathways, genes refer to genes changed significantly in their response to furan between genders
Ingenuity canonical pathway −log (p value) Ratio Genes
NRF2-mediated oxidative stress response 2.27 0.03 GSTA3, MGST1, GPX2, GSTM4, GSTP1
LPS/IL-1-mediated inhibition of RXR function 3.33 0.03 GSTA3, MGST1, LY96, CYP3A7, GSTM4, GSTP1, SULT2A1
Xenobiotic metabolism signaling 2.82 0.02 GSTA3, MGST1, UGT2B4, CYP3A7, GSTM4, GSTP1, SULT2A1
Nicotine degradation 2.38 0.04 UGT2B4, CYP3A7, Aox3
Pyrimidine ribonucleotides 1.89 0.05 NME4, CTPS2
Thyroid hormone metabolism 1.77 0.04 UGT2B7, DIO3
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Comparison of toxicogenomic and apical BMDs
To further explore the utility of toxicogenomics in predict-
ing adverse effects, we compared BMDs for apical end-
points and transcriptional changes in relevant associated 
pathways (Table 5). There was insufficient gene expression 
response to derive pathway BMDs in females; thus, this 
analysis focussed on males only. The analysis showed a 
large degree of consistency between apical and transcrip-
tional BMDs in males, and supports the use of transcrip-
tional BMDs for selection of points of departure as we 
have suggested previously (Bourdon et al. 2012; Jackson 
et al. 2014). In males, the median transcriptional BMDs 
for pathways involved in cell damage response ranged 
from 0.08 to 0.17 mg/kg bw/day, while the BMDs derived 
from modeling histopathological data on Kupffer cell pig-
mentation and hepatocyte apoptosis were 0.03 mg/kg bw/
day. Kupffer cells are resident macrophages in liver and 
function as scavengers for cellular debris and blood-born 
material entering liver. The potential source of the pig-
ment in Kupffer cells seen histologically could be retention 
of bile, lipofuscin, erythrophagocytosis and disintegrated 
hepatocytes (Sobaniec-Lotowska and Lebensztejn 2006). 
Therefore, histological changes, including Kupffer cell pig-
mentation and hepatocyte apoptosis, could correspond to 
transcriptional pathways related to cell damage response. 
The median BMDs for pathways involved in transcriptional 
inflammatory response were 1.1–1.2 mg/kg bw/day, and 
the BMD for ALP (an established marker of liver func-
tion and inflammation, Browning et al. 2008) was 1.49 mg/
kg bw/day. The median transcriptional BMD for bile acid 
biosynthesis was 1.43 mg/kg bw/day, while analysis of bil-
iary tract hyperplasia and cholangiofibrosis yielded BMDs 
of 1.45–1.84 mg/kg bw/day, respectively. Bile acid is 
synthesized in liver, secreted into bile ducts and stored in 
gallbladder. Bile acids secreted in the bile duct are partly 
reabsorbed in the cholangiocytes and recycled back to 
hepatocytes (Chiang 2009). Therefore, abnormal morphol-
ogy of biliary tract and cholangiocytes (hyperplasia and 
fibrosis) may affect synthesis and circulation of bile acids. 
Thus, the BMDs for transcriptional pathways are remark-
ably aligned with the apical endpoints in males. The results 
support the use of toxicogenomic data in identifying mech-
anistically meaningful information to inform hazard char-
acterization and potentially provide effective estimates of 
points of departure in the absence of apical data (Thomas 
et al. 2013).
Effects of furan on miRNA expression
miRNAs are a group of evolutionarily conserved noncod-
ing regulatory RNAs involved in posttranscriptional gene 
regulation that operate via binding to complementary 
regions within target transcripts (Bartel 2004). Transcrip-
tional changes in hepatic miRNAs following furan expo-
sure have been studied previously at both low (2 mg/kg bw/
day for 4 weeks in male F344 rats) and high doses (30 mg/
kg bw/day for 90 days in male SD rats) using PCR arrays 
(Chen et al. 2010, 2012). These studies identified 5 and 
30 miRNAs, respectively, that were significantly changed 
compared to controls. Similarly, we also found minimal 
responses in miRNA at 2 mg/kg bw/day of furan. In our 
study, microarrays detected only a single miRNA signifi-
cantly changed by furan and this single miRNA was not 
altered in previous studies on miRNA response to furan 
(Chen et al. 2010, 2012). Discrepancies may be related to 
differences in the rat strains (F344 vs. SD), treatment dura-
tion (3 months herein vs. 4 weeks) and doses.
The single miRNA significantly changed in our study 
was miR-34a. It was equally affected in both male and 
female rats. As a direct target of P53 transcriptional regu-
lation, miR-34a is a well-known tumor suppressor and is 
involved in apoptosis, cell cycle arrest and senescence 
(Hermeking 2010). High expression is a negative prognos-
tic factor in human hepatocellular carcinoma (Agostini and 
Knight 2014) and is associated with abnormal cell growth 
induced by oxidative stress (Koufaris et al. 2012). The 
findings provide further evidence to support that the car-
cinogenicity of furan mainly results from oxidative stress-
induced apoptosis.
The effects of furan on TH homeostasis
Consistent with observed sex-specific differences on gene 
expression, gender differences were also found in serum 
TH levels following furan treatment. Increased serum levels 
of thyroxin (T4, Gill et al. 2010) were observed in males, 
but not in females. THs are critically important for develop-
ment and maintenance of metabolic balance in mammals. 
To determine the biological impact of the increased circu-
lating TH, we examined the effects of furan on the expres-
sion of genes related to TH action and metabolism.
Although circulating T4 levels increased following furan 
exposure in males, the hepatic transcriptional response 
at least partially indicated a hypothyroid status. Dio1, 
Thrsp and Mlxipl, well-characterized positive TH-respon-
sive genes in liver, were down-regulated in response to 
furan. The mechanism(s) underlying this paradox are not 
clear and were not robustly investigated in this study. An 
increase in circulating TH is probably due to an increase in 
the serum levels of carrier proteins (albumin, transthyretic 
or serpin A7), as the vast majority of circulating T4 is asso-
ciated with these proteins. Clinical biochemistry data con-
firm an increase in albumin levels (Gill et al. 2010). We 
examined the expression of genes involved in TH homeo-
stasis in more detail and found increased expression of 
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Ugt2b7, Dio3, Slco1a4 (Oatp2) and Abcb1b in male rats 
(supplementary Table_S2, Slco1a4 significantly increased 
1.29-fold). The products of these genes increase TH bil-
iary excretion (Ugt2b7; Szabo et al. 2009; Martin et al. 
2012), metabolic deactivation through deiodination (Dio3; 
Crofton 2008), TH uptake (Slco1a4; Abe et al. 1998) and 
efflux (Abcb1b; Mitchell et al. 2005; Ribeiro et al. 1996). 
Therefore, we speculate that increased serum TH levels 
with a concomitant hypothyroid status in liver tissues may 
be due to indirect effects of furan exposure (e.g., metabolic 
enzyme induction) rather than perturbation of the hypotha-
lamic-pituitary-thyroid axis.
Gender differences in response to low doses of furan
Furan induces liver neoplasms in both male and female 
rodents (NTP 1993) at doses equal to or >2 mg/kg bw/
day. Gender differences have been observed, with higher 
incidences and lower BMDs for liver neoplasms occurring 
in male compared to female rodents (Carthew et al. 2010). 
However, the mechanism(s) underlying gender differences in 
liver neoplasms induced by furan is (are) largely unexplored. 
Our study attempted to investigate this issue via dose–
response transcriptional analyses in male and female rats.
In general, we observed that the number of significantly 
changed genes in each dose was about 4–8 times greater in 
males than females. Overall, male livers were clearly cop-
ing with a much higher gene expression response related 
to oxidative stress (and resulting cytotoxicity) than female 
livers. Analyzing basal gene expression levels in control 
males versus females revealed that the top clusters in both 
sexes related to xenobiotic metabolism (Supplementary 
Tabel_S9). Males exhibited significantly higher mRNA 
expression levels of phase I metabolic genes, including 
15 cytochrome p450s (19 exhibiting gender differences in 
total). In contrast, significant overrepresentation of alcohol 
dehydrogenases (for e.g., increased expression of Adh1, 
Adh4, Adh5, Adh6, and Adh7) was found in female livers. 
The Adh family of enzymes provide a general detoxifying 
system for alcohols, bile acid, aldehydes and lipid peroxi-
dation products. In contrast to the cytochrome P450 sys-
tem, Adh enzymes do not generate toxic radicals during 
oxidation reactions (Hoog et al. 2001; Westerlund et al. 
2007). Thus, high basal levels of Adh transcripts may pro-
tect female rats from furan toxicity without causing as sub-
stantial increases in oxidative stress as occurs in males.
Although there appears to be no differences in severity 
of histological lesions between males and females at doses 
≤2 mg/kg bw/day, there does appear to be a slightly higher 
frequency of males showing liver pathology at 2 mg/kg bw/
day (e.g., biliary tract hyperplasia observed in 6 males vs 1 
female) and 0.5 mg/kg bw/day (e.g., basophilic cytoplasm 
of hepatocytes in 8 males vs 0 females), suggesting 
increased sensitivity of males (Gill et al. 2010). We found 
a total of 132 genes that exhibited statistically significant 
differences between genders (supplementary Table_S10). 
This can be attributed to the fact that molecular and his-
tological changes are two independent time-related events. 
Most of these genes had significantly different basal levels 
of expression between genders. The largest gender differ-
ences observed in furan-induced gene expression were 
metallothionein 2A (Mt2a) and glutathione S-transferase 
Yc2 subunit (Gsta5). Among the 132 genes, Akr1b7 and 
Cyp2c12 exhibited the greatest expression differences 
in the livers of female versus male mice (Kwekel et al. 
2010). These genes have some similar features. (1) They 
all have higher basal expression in females; furan expo-
sure triggered increased expression in males, but levels in 
males remained lower than or equal to females (data not 
shown). (2) They all play important roles in detoxification 
(Gsta5, Akr1b7 and Cyp2c12, Endo et al. 2011; Liu et al. 
2009; Lushchak 2012; Schmidt et al. 2011), anti-apoptotic 
effects, anti-oxidative effects and anti-inflammatory actions 
(Mt2a, Endo et al. 2005; Bell and Vallee 2009). Thus, the 
lower overall overt toxicity observed in females following 
furan exposure may be due to protective roles executed by 
these genes. Increased expression of these genes following 
furan exposure in male rats may indicate that furan triggers 
these defense systems as a compensatory response.
Pathways were analyzed for all genes that were dif-
ferently altered by furan treatment in males or females 
separately, or through statistical analysis of genes that 
were significantly different through a direct gender com-
parison of furan-treated rats. Although more than 65 % 
of the pathways that were perturbed in females were 
also perturbed in males, statistical significance and num-
ber of affected genes within the pathways was consist-
ently lower in females (Table 2). Pathway analysis of 
genes exhibiting gender differences in response to furan 
(Table 6) showed that the predominant gender differences 
were in the NRF2-mediated oxidative stress response and 
LPS/IL-1 mediated inhibition of RXR function, in each 
case with effects larger in males than females. Some 
pathways were exclusively activated in males, including 
TH metabolism.
Curated disease models with similar gene expression 
profiles to furan-treated male rats included cancer, inflam-
matory response and injury of liver (Table 4). In females, 
disease models included high-fat diet and injury of liver. 
However, although disease models in females were con-
sistent with males, the correlations between furan exposure 
and disease models were positive in males, but negative in 
females. Thus, the expression profiles are virtually inverted 
for these important disease pathways.
1365Arch Toxicol (2016) 90:1351–1367 
1 3
Overall, the observations indicate that while similar tox-
icological responses are occurring in male and female rats, 
males are more sensitive (enhanced responsiveness at low 
doses in key pathways associated with the MoA) to furan 
toxicity. We speculate that male rats may have progressed 
further down the disease trajectory to liver cancer at the 
time of sampling than female rats.
In conclusion, our toxicogenomics data with doses lower 
or equal to the lowest cancer-causing dose in rats support 
that furan induces liver carcinogenesis through induction 
of gene expression pathways related to oxidative stress 
and inflammatory responses, apoptosis and cellular prolif-
eration. Pathways related to DNA damage response were 
activated only at the highest (carcinogenic) dose in males, 
using our stringent FDR-adjusted approach to identification 
of differentially expressed genes. This approach is useful in 
delineating the most significant pathways involved in toxic-
ity. However, by modeling the data using a BMD approach, 
we clearly show that effects associated with pathways 
involved in cancer are perturbed at doses lower than 2 mg/
kg bw/day. Significant gender differences were identified 
and support that male rats are more sensitive/responsive to 
furan, consistent with the observed increases in histopatho-
logical changes and tumors in male rats. This work is in 
broad support of the ability of toxicogenomics to provide 
insight into MoA and gender differences.
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